A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs Remetinostat (Primary)
- Indications Basal cell cancer; Carcinoma
- Focus Therapeutic Use
- 18 Sep 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 18 Sep 2019 Planned primary completion date changed from 28 Jun 2019 to 28 Jun 2020.
- 13 May 2019 According to a Medivir AB media release, data from the trial presented at has been presented at the 2019 Society for Investigative Dermatology (SID) annual meeting.